- Indication
- Asthma
- RAG rating
- Green
- Document type
- Decision document
- Place
- Hertfordshire and West Essex ICB
- Output type
- Pharmacy / Prescribing
Bibecfo (ICS - beclometasone / LABA - formoterol)
HERTFORDSHIRE AND WEST ESSEX AREA
PRESCRIBING COMMITTEE (HWE APC)
Bibecfo® (ICS - beclometasone / LABA - formoterol) pMDI
(pressurized metered dose inhaler) for treatment of asthma in adults
GREEN
Recommended
for prescribing and treatment considered to be suitable for initiation in
Primary, Community, Secondary or Tertiary care and continuation in Primary
Care.
|
Name generic (trade):
|
Beclometasone / formoterol
|
|
What it is:
|
Inhaled corticosteroid (ICS - beclometasone) & long-acting
β2-agonist (LABA - formoterol) in a pMDI.
|
|
Indication:
|
For treatment of asthma in adults requiring ICS/LABA
for whom a dry powder inhaler (DPI) is unsuitable.
|
|
Date decision last revised:
|
September 2024
|
|
NICE
|
NICE NG245 recommended
|
HWE APC recommendation:
Bibecfo (beclometasone / formoterol) pMDI (pressurized
metered dose inhaler) for treatment of asthma in adults (GREEN status) -
recommended for use: first line pMDI option inhaled corticosteroid (ICS -
beclometasone) & long-acting β2-agonist (LABA - formoterol) for patients
in whom a dry powder inhaler (DPI) is unsuitable; can be used as part of
maintenance therapy (both strengths) & Maintenance & Reliever Therapy
(100/6mcg strength) replacing Luforbec as preferred choice. Equivalent to
originator inhaler Fostair but lower cost.
- Version number
- 1.0
- Developed by
- HWE ICB Pharmacy Medicines Optimisation Team
- Approved by
- HWE ICB Area Prescribing Committee
- Date approved / updated
- September 2024
- Review date
- The recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available
- Superseded version